The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates γ-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells

Clinical Cancer Research

Volumn 9, Issue 16, 2003, Pages 6052-6061

  Jung, Christoph ^a   Motwani, Monica ^a   Kortmansky, Jeremy ^a   Sirotnak, Francis M ^b   She, Yuhong ^b   Gonen, Mithat ^c   Haimovitz Friedman, Adriana ^d   Schwartz, Gary K ^a  

^a Gastrointestinal Oncology Solid Tumor Service   (United States)

^b Program of Molecular Pharmacology and Experimental Therapeutics   (United States)

^c Department of Epidemiology and Biostatistics ^*  (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; FLAVOPIRIDOL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RADIOTHERAPY; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; FLUORESCENCE MICROSCOPY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RADIOSENSITIVITY; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASES; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; CYTOCHROMES C; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; GAMMA RAYS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; STOMACH NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0346734278     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. A. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. (Bethesda), 84: 1736–1740, 1992.
2. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 201: 589–595, 1994.
3. Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L., and Worland, P. J. Flavopiridol induces G1 arrest with inhibition of cyclindependent kinase CDK2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973–2978, 1996.
4. Patel, V., Senderowicz, A. M., and Pinto, D., Jr. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Investig., 102: 1674–1681, 1998.
5. Melillo, G., Sausville, E. A., Cloud, K., Lahusen, T., Varesio, L., and Senderowicz, A. M. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res., 59: 5433–5437, 1999.
6. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between Flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375–3380, 1997.
7. Motwani, M., Delohery, T. M., and Schwartz, G. K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 5: 1876–1883, 1999.
8. Schwartz, G. K., Farsi, K., Maslak, P., Kelsen, D. P., and Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res., 3: 1467–1472, 1997.
9. Motwani, M., Jung, C. P., Gonen, M., Sirotnak, F., and Schwartz, G. K. Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in HCT-116 colon cancer monolayers and xenografts. Clin. Cancer Res., 7: 4209–4219, 2001.
10. Motwani, M., Rizzo, C., Sirotnak, F., She, Y., and Schwartz, G. K. Flavopiridol enhances the effect of docetaxel both in vitro and in vivo in human gastric cancer cells. Mol. Cancer Ther., 2: 549–555, 2003.
11. Chien, M., Astumian, M., Liebowitz, D., Rinker-Schaeffer, C., and Stadler, W. M. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother. Pharmacol., 44: 81–87, 1999.
12. Saltz, L. B., and Minsky, B. Adjuvant therapy of cancers of the colon and rectum. Surg. Clin. N. Am., 82: 1035–1058, 2002.
13. Shah, M. Recent developments in the treatment of gastric carcinoma. Curr. Oncol. Rep., 4: 193–201, 2002.
14. Bains, M. S., Stojadinovic, A., Minsky, B., Rusch, V., Turnbull, A., Korst, R., Ginsberg, R., Kelsen, D. P., and Ilson, D. H. A Phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J. Thorac. Cardiovasc. Surg., 124: 270–277, 2002.
15. Minsky, B. D., Pajak, T. F., Ginsberg, R. J., Pisansky, T. M., Martenson, J., Komaki, R., Okawara, G., Rosenthal, S. A., and Kelsen, D. P. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J. Clin. Oncol., 20: 1167–1174, 2002.
16. Greenberg, M. E. Identification of newly transcribed RNA. In: F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (eds.), Current Protocols in Molecular Biology, pp. 4.10.1–4.10.11. New York: John Wiley & Sons, Inc., 1998.
17. Sirotnak, F. M., DeGraw, J. I., Colwell, W. T., and Piper, J. R. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother. Pharmacol., 42: 313–318, 1998.
18. Pratt, J. W., and Gibbons, J. D. Concepts of Nonparametric Theory. NY: Springer-Verlag, 1981.
19. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304–6311, 1991.
20. Waldman, T., Zhang, Y., Dillehay, L., Yu, J., Kinzler, K., Vogelstein, B., and Williams, J. Cell cycle arrest versus cell death in cancer therapy. Nat. Med., 3: 1034–1036, 1997.
21. Cayrol, C., and Ducommun, B. Interaction with cyclin-dependent kinases and PCNA modulates proteosome-dependent degradation of p21. Oncogene, 12: 2437–2444, 1998.
22. Maki, C. G., and Howley, P. M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol., 17: 355–363, 1997.
23. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. Proteosome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res., 59: 2615–2622, 1999.
24. Zhang, Y., Fujita, N., and Tsuruo, T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene, 18: 1131–1138, 1999.
25. Gervais, J. L. M., Seth, P., and Zhang, H. Cleavage of CDK inhibitor p21WAF1/CIP1 by caspases is an early event during DNA damage- induced apoptosis. J. Biol. Chem., 273: 19207–19212, 1998.
26. Stewart, Z. A., Mays, D., and Pietenpol, J. A. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res., 59: 3831–3837, 1999.
27. Wouters, B. G., Giaccia, A. J., Denko, N. C., and Martin-Brown, J. Loss of p21WAF1/CIP1 sensitizes tumors to radiation by an apoptosisindependent mechanism. Cancer Res., 57: 4703–4706, 1997.
28. Wang, Z., Van Tuyle, G., Conrad, D., Fisher, P. B., Dent, P., and Grant, S. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis. Cancer Res., 59: 1259–1267, 1999.
29. Chao, S. H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793–31799, 2001.
30. Price, D. H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol., 20: 2629–2634, 2000.
31. Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (Wash.DC), 300: 1155–1159, 2003.
32. Bernhard, E. J., McKenna, W. G., and Muschel, R. J. Radiosensitivity and the cell cycle. Cancer J. Sci. Am., 5: 194–204, 1999.
33. Maity, A., Kao, G. D., Muschel, R. J., and McKenna, W. G. Potential molecular targets for manipulating the radiation response. Int. J. Radiat. Oncol. Biol. Phys, 37: 639–653, 1997.
34. Raju, U., Nakata, E., Mason, K. A., Ang, K. K., and Milas, L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res., 63: 3263–3267, 2003.
35. Kim, J., Shah, D., Cao, Q., and Hak, C. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Proc. Am. Assoc. Cancer Res., 44: 32, 2003.